

Financial Statements

For the Second Quarter Ended June 30, 2025

Consolidated Interim Financial Statements

Consol	lidated Interim Balance Sheets	2
Consol	lidated Interim Statements of Earnings (Loss)	3
Consol	lidated Interim Statements of Other Comprehensive Income	4
Consol	lidated Interim Statements of Changes in Total Equity	5
Consol	lidated Interim Statements of Cash Flows	6
Notes t	to the Consolidated Interim Financial Statements	
1	The Company	7
2	Material Accounting Policies	7
3	Accounts Receivable	7
4	Inventories	8
5	Biological Assets	9
6	Investment Property	9
7	Provisions	10
8	Long-Term Debt	11
9	Share Capital	12
10	Financial Instruments and Risk Management	13
11	Interest Expense and Other Financing Costs	15
12	Earnings (Loss) Per Share	15
13	Share-Based Payment	16
14	Geographic and Customer Profile	18
15	Related Party Transactions	18
16	Adjustment of Comparative Information	19

Consolidated Interim Balance Sheets

(In thousands of Canadian dollars) (Unaudited)	Notes	A	As at June 30, 2025		s at June 30, 2024	As at De	ecember 31, 2024	
ASSETS								
Cash and cash equivalents		\$	236,045	\$	158,381	\$	175,908	
Accounts receivable	3		175,559		184,300		170,919	
Notes receivable	3		45,510		44,886		37,978	
Inventories	4		602,370		580,472		553,398	
Biological assets	5		175,550		124,688		169,399	
Income and other taxes recoverable			2,474		62,761		7,551	
Prepaid expenses and other assets			39,155		35,203		42,342	
Assets held for sale			_		27,438		22,769	
Total current assets		\$	1,276,663	\$	1,218,129	\$	1,180,264	
Property and equipment			2,058,069		2,186,520		2,123,167	
Right-of-use assets			149,272		171,692		160,922	
Investments			12,500		16,112		12,763	
Investment property	6		63,488		34,744		42,588	
Employee benefits			15,500		116,800		22,429	
Other long-term assets			23,624		22,271		24,918	
Deferred tax asset			45,808		42,504		46,588	
Goodwill			477,353		477,353		477,353	
Intangible assets			325,055		343,457		339,526	
Total long-term assets		\$	3,170,669	\$	3,411,453	\$	3,250,254	
Total assets		\$	4,447,332	\$	4,629,582	\$	4,430,518	
LIABILITIES AND EQUITY								
Accounts payable and accruals		\$	628,257	\$	543,792	\$	561,179	
Current portion of provisions	7		9,182		9,673		14,482	
Current portion of long-term debt	8		351,673		300,371		301,478	
Current portion of lease obligations			39,710		40,544		39,900	
Income taxes payable			51,955		2,351		2,595	
Other current liabilities			29,342		24,986		37,587	
Total current liabilities		\$	1,110,119	\$	921,717	\$	957,221	
Long-term debt	8	·	1,228,599	·	1,581,093	·	1,390,479	
Lease obligations	-		136,631		157,550		147,892	
Employee benefits			61,837		60,796		62,395	
Provisions	7		3,122		1,998		3,912	
Other long-term liabilities	•		4,961		1,167		5,205	
Deferred tax liability			313,939		330,232		325,137	
Total long-term liabilities		\$	1,749,089	\$	2,132,836	\$	1,935,020	
Total liabilities		\$	2,859,208	\$	3,054,553	\$	2,892,241	
Shareholders' equity		Ψ	2,000,200	Ψ	0,004,000	Ψ	2,002,241	
Share capital	9	\$	904,226	\$	886,876	\$	897,839	
Retained earnings	3	Ψ	631,839	Ψ	640,589	Ψ	587,393	
Contributed surplus			14,049		6,773		12,482	
Accumulated other comprehensive income			38,642					
·					44,222		43,994	
Treasury shares		œ.	(632)	Ф.	(3,431) 1,575,029		(3,431	
Total shareholders' equity		<u>\$</u>	1,588,124	\$		\$	1,538,277	
Total liabilities and equity		\$	4,447,332	\$	4,629,582	\$	4,430,518	

Consolidated Interim Statements of Earnings (Loss)

(In thousands of Canadian dollars, except share amounts)			Three mont	hs en	ided June 30,		Six mont	hs er	nded June 30,
(Unaudited)	Notes		2025		2024 ⁽ⁱ⁾		2025		2024 ⁽ⁱ⁾
Sales		\$	1,362,144	\$	1,255,173	\$	2,603,437	\$	2,402,464
Cost of goods sold		Ψ	1,126,427	Ψ	1,124,018	Ψ	2,149,946	Ψ	2,044,969
Gross profit		\$	235,717	\$	131,155	\$	453,491	\$	357,495
Selling, general and administrative expenses		*	112,966	*	116,649	•	227,773	*	226,682
Earnings before the following:		\$	122,751	\$	14,506	\$	225,718	\$	130,813
Restructuring and other related costs	7		2,705		6,893		4,208		6,168
Other expense (income)			12,789		(3,492)		14,022		(2,335)
Earnings before interest and income taxes		\$	107,257	\$	11,105	\$	207,488	\$	126,980
Interest expense and other financing costs	11		26,234		43,637		55,880		85,720
Earnings (loss) before income taxes		\$	81,023	\$	(32,532)	\$	151,608	\$	41,260
Income tax expense (recovery)			23,245		(6,359)		44,267		15,882
Earnings (loss)		\$	57,778	\$	(26,173)	\$	107,341	\$	25,378
Earnings (loss) per share attributable to common shareholders:	12								
Basic earnings (loss) per share		\$	0.47	\$	(0.21)	\$	0.87	\$	0.21
Diluted earnings (loss) per share		\$	0.46	\$	(0.21)	\$	0.86	\$	0.20
Weighted average number of shares (millions):	12								_
Basic			123.9		122.9		123.8		122.7
Diluted			125.6		122.9		125.3		123.8

⁽i) Adjusted, see Note 16.

Consolidated Interim Statements of Other Comprehensive Income

(In thousands of Canadian dollars)	 Three months	ed June 30,	Six months ended June 30,			
(Unaudited)	2025		2024	2025		2024
Earnings (loss)	\$ 57,778	\$	(26,173)	\$ 107,341	\$	25,378
Other comprehensive (loss) income Actuarial gains (losses) that will not be reclassified to profit or loss (Net of tax of \$2.5 million and \$1.1 million; 2024: \$22.5 million and \$24.7 million)	\$ (7,453)	\$	65,346	\$ (3,319)	\$	71,951
Total items that will not be reclassified to profit or loss	\$ (7,453)	\$	65,346	\$ (3,319)	\$	71,951
Items that are or may be reclassified subsequently to profit or loss: Change in accumulated foreign currency translation adjustment (Net of tax of \$0.0 million and \$0.0 million; 2024: \$0.0 million and \$0.0 million) Change in foreign exchange on long-term debt designated as a net investment hedge (Net of tax of \$2.8 million and \$2.8 million; 2024: \$0.6 million and \$1.8 million)	(20,338) 15,230		3,401	(20,365) 15,343		11,111
Change in cash flow hedges (Net of tax of \$0.0 million and \$0.1 million; 2024: \$0.5 million and \$0.7 million)	(76)		(1,258)	(330)		(4,880)
Total items that are or may be reclassified subsequently to profit or loss	\$ (5,184)	\$	(1,083)	\$ (5,352)	\$	(3,607)
Total other comprehensive (loss) income	\$ (12,637)	\$	64,263	\$ (8,671)	\$	68,344
Comprehensive income	\$ 45,141	\$	38,090	\$ 98,670	\$	93,722

Consolidated Interim Statements of Changes in Total Equity

	Accumulated other comprehensive income (loss)									
(In thousands of Canadian dollars) (Unaudited)	Notes	Share capital		Contributed surplus	Foreign currency translation adjustment ^(/)	Unrealized gains (losses) on cash flow hedges ^(f)	Unrealized gains (losses) on fair value of investments ^(f)	Revaluation surplus	Treasury shares	Total equity
Balance at December 31, 2024		\$897,839	587,393	12,482	14,545	(1,257)	(6,641)	37,347	(3,431)	\$1,538,277
Earnings		_	107,341	_	_	_	_	_	_	107,341
Other comprehensive income (loss) ⁽ⁱⁱ⁾		_	(3,319)	_	(5,022)	(330)	_	_	_	(8,671)
Dividends declared (\$0.48 per share)		5,695	(59,576)	_	_	_	_	_	_	(53,881)
Share-based compensation expense	13	_	_	12,406	_	_	_	_	_	12,406
Deferred taxes on share- based compensation		_	_	3,175	_	_	_	_	_	3,175
Exercise of stock options		692	_	_	_	_	_	_	_	692
Shares purchased by RSU trust		_	_	_	_	_	_	_	(4,094)	(4,094)
Settlement of share-based compensation		_	_	(14,014)	_	_	_	_	6,893	(7,121)
Balance at June 30, 2025		\$904,226	631,839	14,049	9,523	(1,587)	(6,641)	37,347	(632)	\$1,588,124

					Accumula	ted other com	me (loss)			
(In thousands of Canadian dollars) (Unaudited)	Notes	Share capital	Retained earnings	Contributed surplus	Foreign currency translation adjustment ⁽ⁱ⁾	Unrealized gains (losses) on cash flow hedges ⁽ⁱ⁾	Unrealized gains (losses) on fair value of investments ⁽ⁱ⁾	Revaluation surplus	Treasury shares	Total equity
Balance at December 31, 2023		\$873,477	597,429	3,227	8,625	4,416	(2,559)	37,347	(7,183)	\$1,514,779
Earnings		_	25,378	_	_	_	_	_	_	25,378
Other comprehensive income (loss) ⁽ⁱⁱ⁾		_	71,951	_	1,273	(4,880)	_	_	_	68,344
Dividends declared (\$0.44 per share)		10,901	(54,169)	_	_	_	_	_	_	(43,268)
Share-based compensation expense	13	_	_	11,387	_	_	_	_	_	11,387
Deferred taxes on share- based compensation		_	_	(425)	_	_	_	_	_	(425)
Exercise of stock options		2,498	_	_	_	_	_	_	_	2,498
Settlement of share-based compensation		_	_	(7,416)	_	_	_	_	3,752	(3,664)
Balance at June 30, 2024		\$886,876	640,589	6,773	9,898	(464)	(2,559)	37,347	(3,431)	\$1,575,029

⁽i) Items that are or may be subsequently reclassified to profit or loss.

⁽ii) Included in other comprehensive income (loss) is the change in actuarial gains and losses that will not be reclassified to profit or loss and has been reclassified to retained earnings.

Consolidated Interim Statements of Cash Flows

(In thousands of Canadian dollars) Notes 2025 2024 CASH PROVIDED BY (USED IN): Operating activities Earnings (loss) \$ 57,778 \$ (26,173) Add (deduct) items not affecting cash: Change in fair value of biological assets 5 8,087 52,488 Depreciation and amortization 62,103 64,446 Share-based compensation 13 6,629 6,089 Deferred income tax (recovery) expense (8,237) (8,843) Current income tax expense 31,482 2,484 Interest expense and other financing costs 11 26,234 43,637 Gain on sale of long-term assets — (1,326) Impairment of property and equipment and right-of-use assets — (5,038) Change in fair value of long-term assets — (5,038) Change in fair value of non-designated derivatives (744) 2,991 Change in net pension obligation 1,233 2,169	2025 5 107,341 (8,324) 125,757 12,406 (11,954)	\$ 2024
Operating activitiesEarnings (loss)\$ 57,778\$ (26,173)Add (deduct) items not affecting cash:Change in fair value of biological assets58,08752,488Depreciation and amortization62,10364,446Share-based compensation136,6296,089Deferred income tax (recovery) expense(8,237)(8,843)Current income tax expense31,4822,484Interest expense and other financing costs1126,23443,637Gain on sale of long-term assets—(1,326)Impairment of property and equipment and right-of-use assets—(5,038)Change in fair value of long-term assets—(5,038)Change in fair value of non-designated derivatives(744)2,991Change in net pension obligation1,2332,169	(8,324) 125,757 12,406	\$ 25,378
Earnings (loss) \$ 57,778 \$ (26,173) Add (deduct) items not affecting cash: Change in fair value of biological assets 5 8,087 52,488 Depreciation and amortization 62,103 64,446 Share-based compensation 13 6,629 6,089 Deferred income tax (recovery) expense (8,237) (8,843) Current income tax expense 31,482 2,484 Interest expense and other financing costs 11 26,234 43,637 Gain on sale of long-term assets — (1,326) Impairment of property and equipment and right-of-use assets — (5,038) Change in fair value of long-term assets Change in fair value of non-designated derivatives (744) 2,991 Change in net pension obligation 1,233 2,169	(8,324) 125,757 12,406	\$ 25,378
Add (deduct) items not affecting cash: Change in fair value of biological assets Depreciation and amortization Share-based compensation Deferred income tax (recovery) expense Current income tax expense Interest expense and other financing costs Interest expense and other financing costs Impairment of property and equipment and right-of-use assets Change in fair value of long-term assets Change in fair value of non-designated derivatives Change in net pension obligation 52,488 62,103 64,446 62,103 64,446 68,237) (8,843) 2,484 11 26,234 43,637 — (1,326) 1,291 118 Change in fair value of long-term assets Change in fair value of non-designated derivatives (744) 2,991 Change in net pension obligation	(8,324) 125,757 12,406	\$ 25,378
Change in fair value of biological assets Depreciation and amortization Share-based compensation Deferred income tax (recovery) expense Current income tax expense Interest expense and other financing costs Impairment of property and equipment and right-of-use assets Change in fair value of long-term assets Change in fair value of non-designated derivatives Change in net pension obligation Change in net pension obligation 5 8,087 62,103 64,446 62,103 6,629 6,089 (8,237) (8,843) 2,484 11 26,234 43,637	125,757 12,406	
Depreciation and amortization Share-based compensation 13 6,629 6,089 Deferred income tax (recovery) expense Current income tax expense Interest expense and other financing costs Impairment of property and equipment and right-of-use assets Change in fair value of long-term assets Change in fair value of non-designated derivatives Change in net pension obligation 62,103 64,446 6,089	125,757 12,406	
Share-based compensation 13 6,629 6,089 Deferred income tax (recovery) expense (8,237) (8,843) Current income tax expense 31,482 2,484 Interest expense and other financing costs 11 26,234 43,637 Gain on sale of long-term assets — (1,326) Impairment of property and equipment and right- of-use assets 1,291 118 Change in fair value of long-term assets — (5,038) Change in fair value of non-designated derivatives (744) 2,991 Change in net pension obligation 1,233 2,169	12,406	(16,655)
Deferred income tax (recovery) expense (8,237) (8,843) Current income tax expense 31,482 2,484 Interest expense and other financing costs 11 26,234 43,637 Gain on sale of long-term assets — (1,326) Impairment of property and equipment and right- of-use assets 1,291 118 Change in fair value of long-term assets — (5,038) Change in fair value of non-designated derivatives (744) 2,991 Change in net pension obligation 1,233 2,169		130,299
Current income tax expense 31,482 2,484 Interest expense and other financing costs 11 26,234 43,637 Gain on sale of long-term assets — (1,326) Impairment of property and equipment and right- of-use assets 1,291 118 Change in fair value of long-term assets — (5,038) Change in fair value of non-designated derivatives (744) 2,991 Change in net pension obligation 1,233 2,169	(11,954)	11,387
Interest expense and other financing costs Gain on sale of long-term assets Impairment of property and equipment and right- of-use assets Change in fair value of long-term assets Change in fair value of non-designated derivatives Change in net pension obligation 126,234 43,637 1,291 1,291 118 (5,038) (744) 2,991 1,233 2,169		11,093
Gain on sale of long-term assets — (1,326) Impairment of property and equipment and right- of-use assets 1,291 118 Change in fair value of long-term assets — (5,038) Change in fair value of non-designated derivatives (744) 2,991 Change in net pension obligation 1,233 2,169	56,221	4,789
Impairment of property and equipment and right- of-use assets Change in fair value of long-term assets Change in fair value of non-designated derivatives (744) Change in net pension obligation 1,233 1,291 118 (5,038) (744) 2,991 1,233	55,880	85,720
of-use assets Change in fair value of long-term assets Change in fair value of non-designated derivatives Change in net pension obligation 1,291 (5,038) (744) 2,991 1,233 2,169	(10,609)	(1,637)
Change in fair value of non-designated derivatives (744) 2,991 Change in net pension obligation 1,233 2,169	2,157	118
derivatives (744) 2,991 Change in net pension obligation 1,233 2,169	_	(5,038)
Change in net pension obligation 1,233 2,169	378	(1,674)
	1,952	3,236
Not income taxes (naid) retuinded 12701 18 76/	(1,594)	21,746
Net income taxes (paid) refunded (229) 18,764 Interest paid, net of capitalized interest 11 (26,127) (32,459)	(54,700)	(72,936)
Change in provision for restructuring and other	(34,700)	(72,930)
related costs 7 (1,788) 3,087	(6,051)	(173)
Change in derivatives margin 3,650 (1,075)	2,039	1,241
Cash settlement of derivatives — (728)	_	(2,878)
Other (23,549) 2,231	(18,404)	5,324
Change in non-cash operating working capital 101,774 (77,366)	(3,025)	(66,519)
Cash provided by operating activities \$ 239,587 \$ 45,496	249,470	\$ 132,821
Investing activities		
Additions to long-term assets \$ (24,433) \$ (16,318)	(49,285)	\$ (40,131)
Interest paid and capitalized 11 (303) (219)	(583)	(574)
Proceeds from sale of long-term assets 1,750 2,631	14,754	3,496
Cash used in investing activities \$ (22,986) \$ (13,906)	(35,114)	\$ (37,209)
Financing activities		
Dividends paid \$ (27,150) \$ (21,607)	(53,881)	\$ (43,268)
Net decrease in long-term debt 8 (60,265) (50,480)	(80,047)	(81,365)
Payment of lease obligation (8,091) (7,891)	(16,183)	(16,337)
Exercise of stock options 534 2,498	534	2,498
Purchase of treasury shares (4,094) —	(4,094)	_
Payment of financing fees 8 (541) (2,122)	(548)	(2,122)
Cash used in financing activities \$ (99,607) \$ (79,602)	(154,219)	\$ (140,594)
Increase (decrease) in cash and cash equivalents \$ 116,994 \$ (48,012)		
Cash and cash equivalents, beginning of period 119,051 206,393	60,137	\$ (44,982)
Cash and cash equivalents, end of period \$ 236,045 \$ 158,381	60,137 175,908	\$ (44,982) 203,363

Notes to the Consolidated Interim Financial Statements

(Tabular amounts in thousands of Canadian dollars unless otherwise indicated) Three and six months ended June 30, 2025 and 2024

1. THE COMPANY

Maple Leaf Foods Inc. ("Maple Leaf Foods" or the "Company") is a leading protein company responsibly producing food products under leading brands including Maple Leaf®, Maple Leaf Prime®, Maple Leaf Natural Selections®, Schneiders®, Mina®, Greenfield Natural Meat Co.®, Lightlife® and Field Roast™. The Company's portfolio includes prepared meats, ready-to-cook and ready-to-serve meals, snack kits, value-added fresh pork and poultry, and plant protein products. The address of the Company's registered office is 6897 Financial Dr., Mississauga, Ontario, L5N 0A8, Canada. The unaudited condensed consolidated interim financial statements ("Consolidated Interim Financial Statements") of the Company as at and for the three and six months ended June 30, 2025 include the accounts of the Company and its subsidiaries.

2. MATERIAL ACCOUNTING POLICIES

The Consolidated Interim Financial Statements should be read in conjunction with the Company's 2024 Annual Audited Consolidated Financial Statements ("2024 Consolidated Financial Statements").

(a) Statement of Compliance

The Consolidated Interim Financial Statements have been prepared in accordance with International Accounting Standard ("IAS") 34 Interim Financial Reporting ("IAS 34") as issued by the International Accounting Standards Board ("IASB") and using the accounting policies, determination of significant estimates and judgments, and corresponding accounting treatments consistent with the Company's 2024 Consolidated Financial Statements.

The Consolidated Interim Financial Statements were authorized for issue by the Board of Directors on August 6, 2025.

(b) Accounting Pronouncements Issued But Not Yet Effective

Presentation and Disclosure in Financial Statements - IFRS 18

On April 9, 2024, the IASB issued IFRS 18 *Presentation and Disclosure in Financial Statements* to improve reporting of financial performance. IFRS 18 replaces IAS 1 *Presentation of Financial Statements*. It carries forward many requirements from IAS 1 unchanged and introduces significant changes to the structure of a company's income statement, more discipline and transparency in presentation of management's own performance measures, commonly referred to as 'non-GAAP measures', and less aggregation of items into large, single numbers. IFRS 18 applies for annual reporting periods beginning on or after January 1, 2027 with the requirement of retrospective restatement. Earlier application is permitted. The Company currently intends to adopt this amendment in its Consolidated Interim Financial Statements for the period beginning January 1, 2027. The Company has yet to assess the impact of adoption on the Consolidated Interim Financial Statements.

All other IFRSs and amendments issued but not yet effective have been assessed by the Company and are not expected to have a material impact on the Consolidated Interim Financial Statements.

3. ACCOUNTS RECEIVABLE

	As at June 30,		As a	t June 30,	As at Dec	ember 31,	
		2025		2024		2024	
Trade receivables	\$	147,350	\$	143,337	\$	130,409	
Less: Allowance for doubtful accounts		(2,783)		(2,111)		(2,119)	
Net trade receivables	\$	144,567	\$	141,226	\$	128,290	
Other receivables:							
Commodity taxes receivable		13,426		12,536		13,911	
Government receivable		154		10,589		11,096	
Other		17,412		19,949		17,622	
	\$	175,559	\$	184,300	\$	170,919	

The aging of trade receivables is as follows:

	As at June 30,		As at June 30,		As at Dece	ember 31,
		2025		2024		2024
Current	\$	116,365	\$	119,621	\$	97,968
Past due 0-30 days		20,951		14,257		23,640
Past due 31-60 days		4,011		4,821		2,578
Past due > 60 days		6,023		4,638		6,223
	\$	147,350	\$	143,337	\$	130,409

Trade receivables are impaired when their estimated future cash flows are less than their contractual cash flows. The amount of impairment takes into account the financial condition of the customers, delinquencies in payments, collaterals and credit insurance coverage on trade receivables.

On May 31, 2024, the Company renewed its accounts receivable securitization facility (the "Securitization Facility") extending its maturity to May 31, 2026. The maximum cash advance available to the Company under the Securitization Facility is \$150.0 million (June 30, 2024: \$150.0 million; December 31, 2024: \$150.0 million). The Securitization Facility provides cash funding with a proportion of the Company's receivables being sold, provides the Company with competitively priced financing and further diversifies its funding sources. Under the Securitization Facility, the Company has sold certain of its trade accounts receivable, with very limited recourse, to an unconsolidated third-party trust financed by an international financial institution with a long-term AA- debt rating, for cash and short-term notes back to the Company. The receivables are sold at a discount to face value based on prevailing money market rates. The Company retains servicing responsibilities for these receivables.

As at June 30, 2025, trade accounts receivable being serviced under this program amounted to \$172.0 million (June 30, 2024: \$155.3 million; December 31, 2024: \$129.2 million). As consideration for the sale of its trade receivables, the Company will receive cash advances of \$126.5 million (June 30, 2024: \$110.4 million; December 31, 2024: \$91.2 million) and notes receivable in the amount of \$45.5 million (June 30, 2024: \$44.9 million; December 31, 2024: \$38.0 million). The notes receivable are non-interest bearing and are settled on the settlement dates of the securitized accounts receivable. Due to the timing of receipts and disbursements, the Company may, from time to time, also record a receivable or payable related to the Securitization Facility. As at June 30, 2025, the Company recorded a net payable in the amount of \$39.3 million (June 30, 2024: \$23.9 million net payable; December 31, 2024: \$59.8 million net payable) in accounts payable and accruals (June 30, 2024: accounts payable and accruals; December 31, 2024: accounts payable and accruals).

The sale of trade receivables under the Securitization Facility are treated as a sale from an accounting perspective and as a result, trade receivables sold under this facility are derecognized from the unaudited condensed consolidated interim balance sheets ("Consolidated Interim Balance Sheets") as at June 30, 2025 and 2024 and the 2024 annual audited consolidated balance sheet as at December 31, 2024.

4. INVENTORIES

	As at	As at June 30,		t June 30,	As at Dec	ember 31,	
		2025		2024		2024	
Raw materials	\$	73,441	\$	74,702	\$	60,552	
Work in process		50,863		44,824		46,926	
Finished goods		341,213		334,284		319,529	
Packaging		39,947		34,929		32,893	
Spare parts		96,906		91,733		93,498	
	\$	602,370	\$	580,472	\$	553,398	

For the three months ended June 30, 2025, inventory in the amount of \$1,045.1 million (2024: \$985.0 million) was expensed through cost of goods sold.

For the six months ended June 30, 2025, inventory in the amount of \$1,979.7 million (2024: \$1,894.8 million) was expensed through cost of goods sold.

As at June 30, 2025, inventories have been reduced by \$13.7 million (June 30, 2024: \$14.7 million; December 31, 2024: \$16.2 million) as a result of write-downs to net realizable value. The write-downs are included in the amount expensed through cost of goods sold.

5. BIOLOGICAL ASSETS

The change in fair value of commercial hog stock for the three months ended June 30, 2025 was a loss of \$8.1 million (2024: loss of \$52.5 million) and was recorded in cost of goods sold.

The change in fair value of commercial hog stock for the six months ended June 30, 2025 was a gain of \$8.3 million (2024: gain of \$16.7 million) and was recorded in cost of goods sold.

The fair value measures of commercial hog stock have been categorized as a Level 3 fair value based on inputs to the valuation techniques used. There were no transfers between levels for the three and six months ended June 30, 2025 and June 30, 2024.

6. INVESTMENT PROPERTY

	As at c	June 30, 2025
Net balance, December 31, 2024	\$	42,588
Net balance, March 31, 2025	\$	42,588
Transfer from assets held for sale	\$	20,900
Net balance, June 30, 2025	\$	63,488
	As at .	June 30, 2024
Net balance, December 31, 2023	\$	57,144
Net balance, March 31, 2024	\$	57,144
Transfer to assets held for sale	\$	(22,400)
Net balance, June 30, 2024	\$	34.744

The fair value measurement of investment properties has been categorized as a Level 3 fair value based on inputs to the valuation techniques used. There have been no changes to the valuation techniques and there have not been any transfers between levels for the three months ended June 30, 2025 and June 30, 2024.

The Company's investment properties did not earn a material amount of rental income, nor did they incur a material amount of expenses in either of the current or the prior year.

7. PROVISIONS

		-	Restructuring and related provisions			
	Enviro	onmental	Severance and other employee related costs	Site closing and other cash costs		Total
Balance at December 31, 2024 ⁽ⁱ⁾	\$	1,978	16,225	191	\$	18,394
Charges		_	562	86		648
Reversals		_	(205)	_		(205)
Cash payments		(19)	(4,524)	(182)		(4,725)
Balance at March 31, 2025	\$	1,959	12,058	95	\$	14,112
Charges		_	2,162	489		2,651
Reversals		_	(545)	_		(545)
Cash payments		(20)	(3,551)	(341)		(3,912)
Foreign currency translation		_	_	(2)		(2)
Balance at June 30, 2025	\$	1,939	10,124	241	\$	12,304
Current					\$	9,182
Non-current						3,122
Total at June 30, 2025					\$	12,304

^(f) Balance as at December 31, 2024, includes current portion of \$14.5 million and non-current portion of \$3.9 million.

		_	Restructuring provisi		
	Envir	ronmental	Severance and other employee related costs	Site closing and other cash costs	Total
Balance at December 31, 2023 ⁽ⁱ⁾	\$	2,041	9,846	_	\$ 11,887
Charges		_	283	501	784
Reversals		_	(1,501)	_	(1,501)
Cash payments		(4)	(2,048)	(501)	(2,553)
Foreign currency translation		_	6	_	6
Balance at March 31, 2024	\$	2,037	6,586	_	\$ 8,623
Charges		_	4,521	356	4,877
Reversals		_	(99)	_	(99)
Cash payments		(39)	(1,437)	(256)	(1,732)
Foreign currency translation		_	2	_	2
Balance at June 30, 2024	\$	1,998	9,573	100	\$ 11,671
Current					\$ 9,673
Non-current Non-current					1,998
Total at June 30, 2024					\$ 11,671

⁽ⁱ⁾ Balance as at December 31, 2023, includes current portion of \$9.8 million and non-current portion of \$2.0 million.

Restructuring and Other Related Costs

During the three months ended June 30, 2025, the Company recorded restructuring and other related costs of \$2.7 million. Of this, \$2.2 million in severance and other employee costs related to the reorganization of its commercial and operations teams. A further \$0.8 million of net charges was comprised of \$0.6 million in accelerated depreciation and \$0.4 million of decommissioning costs, and offset by a reversal of \$0.2 million related to severance and other employee costs, associated with the previously announced closure of the Company's further processed poultry facility in Brantford, Ontario. The remaining reversals relate to employee costs for the closures of the Brampton, Toronto, St. Mary's, and Schomberg poultry plants.

During the three months ended June 30, 2024, the Company recorded restructuring and other related costs of \$6.9 million. Of this, \$6.1 million of severance and other employee costs and \$0.5 million of accelerated depreciation related to the closure of the Brantford plant. A further expense of \$0.3 million related to decommissioning costs, incurred for the closures of the Brampton, Toronto, St. Mary's and Schomberg poultry plants.

During the six months ended June 30, 2025, the Company recorded restructuring and other related costs of \$4.2 million. Of this, \$2.6 million in severance and other employee costs related to the reorganization of its commercial and operations teams. A further \$1.8 million of net charges was comprised of \$1.6 million in accelerated depreciation and \$0.5 million of decommissioning costs, offset by a reversal of \$0.3 million related to severance and other employee costs, associated with the closure of the Brantford plant. The remaining reversals relate to employee costs due to closures of the Brampton, Toronto, St. Mary's, and Schomberg poultry plants.

During the six months ended June 30, 2024, the Company recorded restructuring and other related costs of \$6.2 million. Of this, \$6.1 million of severance and other employee costs and \$0.5 million of accelerated depreciation related to the closure of the Brantford plant. A net reversal of \$0.6 million related to the closures of the Brampton, Toronto, St. Mary's and Schomberg poultry plants and was comprised of \$0.8 million of decommissioning costs, offset by a reversal of \$1.3 million related to severance and other employee costs and a reversal of \$0.1 million related to asset impairments. The remaining amount of \$0.2 million related to employee costs and inventory impairment for other previous organizational restructuring initiatives.

8. LONG-TERM DEBT

	As at June 30,		As at December 31,
	2025	2024	2024
Revolving line of credit	\$ 861,398	\$ 863,400	\$ 652,000
U.S. term credit Tranche 1	361,049	362,692	381,030
Canadian term credit Tranche 2	350,000	350,000	350,000
Canadian term credit Tranche 3	_	300,000	300,000
Government loans	5,875	6,628	6,208
Supplier financing	4,479	3,607	6,167
Deferred financing charges	(2,529)	(4,863)	(3,448)
Total long-term debt	\$ 1,580,272	\$ 1,881,464	\$ 1,691,957
Current	\$ 351,673	\$ 300,371	\$ 301,478
Non-current	1,228,599	1,581,093	1,390,479
Total long-term debt	\$ 1,580,272	\$ 1,881,464	\$ 1,691,957

The Company has a syndicated sustainability-linked credit facility (the "Credit Facility") consisting of a \$1,300.0 million unsecured committed revolving line of credit maturing June 29, 2027, and two unsecured committed term facilities for \$350.0 million (Tranche 2) and US\$265.0 million (Tranche 1) maturing June 29, 2026 and June 29, 2027, respectively. On June 20, 2023, the Credit Facility was amended by adding an additional \$400.0 million unsecured committed term credit (Tranche 3) maturing June 20, 2024, and adjusting the financial covenants to facilitate access to the new tranche. On April 30, 2024 the Company amended its Credit Facility, downsizing Tranche 3 to \$300.0 million and extending it's maturity to June 20, 2025. On June 20, 2025, the Company fully repaid the \$300.0 million term credit (Tranche 3) at its maturity.

The Credit Facility may be drawn in Canadian or U.S. dollars and bears interest payable monthly, based on Canadian Overnight Repo Rate Average ("CORRA") and Prime rates for Canadian dollar loans and based on the Secured Overnight Financing Rate ("SOFR") for U.S. dollar loans. The Credit Facility is intended to meet the Company's funding requirements for capital investments in addition to providing appropriate levels of liquidity for general corporate purposes. The interest rate on the Credit Facility may be adjusted up or down by a maximum of 5 basis points based on the Company's performance compared to specified sustainability targets.

In addition to the borrowings on the revolving facility and the term credit, as at June 30, 2025 the Company had drawn letters of credit of \$9.0 million on the Credit Facility (June 30, 2024: \$9.1 million; December 31, 2024: \$9.1 million).

The Credit Facility requires the maintenance of certain covenants. As at June 30, 2025, the Company was in compliance with all of these covenants. The primary financial covenant requires that the Company maintain a net debt to capitalization ratio below a specified threshold.

The Company has additional uncommitted credit facilities for issuing letters of credit up to a maximum of \$105.0 million (June 30, 2024: \$105.0 million; December 31, 2024: \$105.0 million). As at June 30, 2025, \$47.2 million in letters of credit had been issued thereon (June 30, 2024: \$47.0 million; December 31, 2024: \$47.6 million).

As at June 30, 2025, the Company has one non-interest bearing government loan of \$5.9 million (June 30, 2024: \$6.6 million; December 31, 2024: \$6.2 million) still outstanding and maturing in 2033. The facility is committed.

The following table reconciles the changes in cash flows from financing activities for long-term debt for the period in the respective years:

	Three months ended June 30, Six months ended J						ed June 30,	
		2025		2024		2025		2024
Total long-term debt, beginning of period	\$	1,672,710	\$	1,929,203	\$	1,691,957	\$	1,950,815
Revolving and term credit facilities - net repayments	\$	(60,000)	\$	(50,000)	\$	(78,252)	\$	(80,000)
Government loans repayments		(222)		(480)		(444)		(647)
Supplier financing repayments		(43)		_		(1,351)		(718)
Payment of financing fees		(541)		(2,122)		(548)		(2,122)
Total cash outflow from long-term debt financing activities	\$	(60,806)	\$	(52,602)	\$	(80,595)	\$	(83,487)
Foreign exchange revaluation	\$	(32,344)	\$	3,786	\$	(32,668)	\$	11,942
Other non-cash changes		712		1,077		1,578		2,194
Total non-cash changes	\$	(31,632)	\$	4,863	\$	(31,090)	\$	14,136
Total long-term debt, end of period	\$	1,580,272	\$	1,881,464	\$	1,580,272	\$	1,881,464

9. SHARE CAPITAL

Share Repurchase

On March 11, 2025 the Toronto Stock Exchange ("TSX") accepted the Company's notice of intention to commence a Normal Course Issuer Bid ("NCIB"), allowing the Company to repurchase, at its discretion, up to 7.3 million common shares in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. Common shares purchased by the Company are cancelled. The program commenced on March 13, 2025 and will terminate on March 12, 2026. Under this bid, during the three and six months ended June 30, 2025, no shares were repurchased for cancellation.

On May 20, 2023 the TSX accepted the Company's notice of intention to commence a NCIB, allowing the Company to repurchase, at its discretion, up to 7.2 million common shares in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. Common shares purchased by the Company are cancelled. The program commenced on May 25, 2023 and terminated on May 24, 2024. Under this bid, during the three and six months ended June 30, 2024, no shares were repurchased for cancellation.

10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company applies hedge accounting as appropriate and uses derivatives and other non-derivative financial instruments to manage its exposures to fluctuations in foreign exchange rates, interest rates, and commodity prices.

The fair values and notional amounts of derivative financial instruments as at June 30 are shown below:

	2025					2	2024				
	Notional		Fair v	/alu	ie	Notional		Fair va		/alu	Э
	amount ⁽ⁱ⁾		Asset ⁽ⁱⁱ⁾	L	iability ⁽ⁱⁱ⁾		amount ⁽ⁱ⁾		Asset ⁽ⁱⁱ⁾	L	iability ⁽ⁱⁱ⁾
Cash flow hedges											
Foreign exchange contracts	\$ 59,099	\$	685	\$	1	\$	70,473	\$	_	\$	631
Commodity contracts	\$ 17,583		_		1,832	\$	_		_		_
Interest rate swaps	\$ 400,000		3,489		5,492	\$	_		_		_
		\$	4,174	\$	7,325			\$		\$	631
Fair value hedges ⁽ⁱⁱⁱ⁾											
Foreign exchange contracts	\$ 45,897	\$	1,447	\$	4	\$	23,887	\$	2	\$	260
Commodity contracts	\$ 43,332		_		2,562	\$	22,153		2,490		_
		\$	1,447	\$	2,566			\$	2,492	\$	260
Derivatives not designated in a											
formal hedging relationship											
Interest rate swaps	\$ 222,625	\$	_	\$	1,223	\$	_	\$	_	\$	_
Foreign exchange contracts	\$ 134,847		429		700	\$	153,073		556		36
Commodity contracts	\$ 162,973		8,084		_	\$	256,979		_		2,293
		\$	8,513	\$	1,923			\$	556	\$	2,329
Total fair value		\$	14,134	\$	11,814			\$	3,048	\$	3,220
Current ^{(ii)(iv)}		\$	12,399	\$	8,917			\$	3,048	\$	3,220
Non-current ⁽ⁱⁱ⁾			1,735		2,897				_		_
Total fair value		\$	14,134	\$	11,814			\$	3,048	\$	3,220

⁽I) Unless otherwise stated, notional amounts are stated at the contractual Canadian dollar equivalent.

During the three months ended June 30, 2025, the Company recorded a pre-tax loss of \$0.4 million (2024: gain of \$1.3 million) on non-designated financial instruments held for trading.

During the six months ended June 30, 2025, the Company recorded a pre-tax loss of \$3.1 million (2024: gain of \$7.2 million) on non-designated financial instruments held for trading.

During the three and six months ended June 30, 2025 and 2024, hedge ineffectiveness was negligible.

The current portion of derivative assets and liabilities are recorded in prepaid expenses and other assets and other current liabilities, respectively, in the Consolidated Interim Balance Sheets and will impact earnings at various dates within the next 12 months. The non-current portion of derivative assets and liabilities are recorded in other long-term assets and other long-term liabilities, respectively, in the Consolidated Interim Balance Sheets.

⁽iii) The carrying amount of the hedged items in the Consolidated Interim Balance Sheets are recorded at the inverse of the associated hedging instruments and are equal to the accumulated fair value hedge adjustments less hedge ineffectiveness.

⁽iv) As at June 30, 2025, the above fair value of current assets has been decreased by \$6.0 million (June 30, 2024: decreased by \$0.3 million; December 31, 2024: increased by \$1.1 million), and the above fair value of current liabilities has been decreased by \$4.4 million (June 30, 2024: decreased by \$2.3 million; December 31, 2024: decreased by \$0.0 million) on the Consolidated Interim Balance Sheets, representing the difference in the fair market value of exchange traded commodity contracts and the initial margin requirements. The difference in margin requirements and fair market value is net settled in cash each day with the futures exchange and is recorded within cash and cash equivalents.

The table below sets out fair value measurements of derivative financial instruments as at June 30, 2025 using the fair value hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Foreign exchange contracts	\$ _	2,561	_	\$ 2,561
Commodity contracts ⁽ⁱ⁾	3,690	_	_	3,690
Interest rate swaps	_	3,489	_	3,489
	\$ 3,690	6,050	_	\$ 9,740
Liabilities:				
Foreign exchange contracts	\$ _	705	_	\$ 705
Interest rate swaps	_	6,715	_	6,715
	\$ _	7,420	_	\$ 7,420

Level 1 commodity contracts are net settled and recorded as a net asset or liability on the Consolidated Interim Balance Sheets.

There were no transfers between levels for the three and six months ended June 30, 2025 and June 30, 2024.

Determination of fair value and the resulting hierarchy requires the use of observable market data whenever available. The classification of a financial instrument in the hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. For financial instruments that are recognized at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization at the end of each reporting period.

Accumulated other comprehensive income

The Company estimates that \$0.8 million, net of tax of \$0.3 million, of the unrealized loss included in accumulated other comprehensive income will be reclassified into earnings within the next 12 months. The actual amount of this reclassification will be impacted by future changes in the fair value of financial instruments designated as cash flow hedges. The actual amount reclassified could differ from this estimated amount.

During the three months ended June 30, 2025, a loss of \$0.1 million, net of tax of \$0.0 million, was released to loss from accumulated other comprehensive income (loss) and included in the net change for the year (2024: gain of \$0.8 million, net of tax of \$0.3 million).

During the six months ended June 30, 2025, a loss of \$1.0 million, net of tax of \$0.3 million, was released to earnings from accumulated other comprehensive income and included in the net change for the year (2024: gain of \$3.8 million, net of tax of \$1.3 million).

As at June 30, 2025, the Company had US\$265.0 million (June 30, 2024: US\$265.0 million; December 31, 2024: US\$265.0) drawn on the Credit Facility of which US\$241.7 million (June 30, 2024: US\$258.3 million; December 31, 2024: US\$245.2 million) is designated as a net investment hedge of the Company's U.S. operations. Foreign exchange gains and losses on the designated drawings are recorded in accumulated other comprehensive income and offset translation adjustments on the underlying net assets of the U.S. operations, which are also recorded in accumulated other comprehensive income.

During the three months ended June 30, 2025, the gain on the net investment hedge recorded in other comprehensive income (loss) was \$15.2 million, net of tax of \$2.8 million (2024: loss of \$3.2 million, net of tax of \$0.6 million).

During the six months ended June 30, 2025, the gain on the net investment hedge recorded in other comprehensive income was \$15.3 million, net of tax of \$2.8 million (2024: loss of \$9.8 million, net of tax of \$1.8 million).

11. INTEREST EXPENSE AND OTHER FINANCING COSTS

	Three months ended June 30,			June 30,	Six months ended June 30,			
		2025		2024	2025		2024	
Interest on borrowings from credit facility	\$	21,787	\$	38,012	\$ 46,550	\$	74,934	
Interest on lease obligations		1,985		2,174	4,038		4,032	
Interest on securitized receivables		1,216		1,680	2,481		3,326	
Interest on government loans		55		62	111		128	
Amortization of deferred financing charges		680		1,015	1,490		2,066	
Credit facility standby fees and other interest		814		913	1,793		1,808	
	\$	26,537	\$	43,856	\$ 56,463	\$	86,294	
Interest paid and capitalized		(303)		(219)	(583)		(574)	
	\$	26,234	\$	43,637	\$ 55,880	\$	85,720	

Interest paid during the three and six months ended June 30, 2025 was \$26.4 million and \$55.3 million (2024: \$32.7 million and \$73.5 million).

12. EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share amounts are calculated by dividing the earnings (loss) of the Company by the weighted average number of shares outstanding during the period.

Diluted earnings (loss) per share amounts are calculated by dividing the earnings (loss) of the Company by the weighted average number of shares outstanding during the period, adjusted for the effects of potentially dilutive instruments.

The following table sets forth the calculation of basic and diluted earnings (loss) per share ("EPS"):

		2025			2024	
Three months ended June 30,	Earnings	Weighted average number of shares ⁽ⁱ⁾	EPS	(Loss) Earnings	Weighted average number of shares ⁽ⁱ⁾	EPS
Basic	\$ 57,778	123.9	\$ 0.47	\$ (26,173)	122.9	\$ (0.21)
Effect of dilutive securities(ii)		1.7			_	
Diluted	\$ 57,778	125.6	\$ 0.46	\$ (26,173)	122.9	\$ (0.21)
Six months ended June 30,						
Basic	\$ 107,341	123.8	\$ 0.87	\$ 25,378	122.7	\$ 0.21
Effect of dilutive securities(ii)		1.5			1.1	
Diluted	\$ 107,341	125.3	\$ 0.86	\$ 25,378	123.8	\$ 0.20

⁽i) In millions.

⁽ii) Excludes the effect of approximately 5.2 million (2024: 7.4 million) stock options and restricted share units that are anti-dilutive for the three months ended June 30, 2025 and 5.3 million (2024: 6.0 million) for the six months ended June 30, 2025.

13. SHARE-BASED PAYMENT

Stock Options

A summary of the status of the Company's outstanding stock options for the for the six months ended June 30 are presented below:

	202	2025		
	Options outstanding	Weighted average exercise price	Options outstanding	Weighted average exercise price
Outstanding at January 1	7,299,200	\$25.62	6,537,050	\$26.83
Granted	870,300	\$24.64	1,793,850	\$22.95
Forfeited	(3,450)	\$22.95	(107,850)	\$25.57
Expired	(664,950)	\$ 32.50	(677,100)	\$30.86
Outstanding at March 31	7,501,100	\$24.90	7,545,950	\$25.56
Exercised	(23,550)	\$22.95	(108,200)	\$23.08
Forfeited	(4,500)	\$22.95	_	\$ —
Expired	_	\$ —	(90,100)	\$25.22
Outstanding at June 30	7,473,050	\$24.90	7,347,650	\$25.60
Options currently exercisable	5,171,850	\$ 25.43	4,797,900	\$26.63

All outstanding stock options vest and become exercisable over a period not exceeding five years (time vesting) from the date of grant. The outstanding options have a term of seven years.

At grant date, each option series is measured at fair value based on the Black-Scholes formula. Expected volatility is estimated by considering historic average share price volatility. The inputs used in this model for the options granted during the six months ended June 30, 2025 and 2024 are shown in the table below⁽ⁱ⁾:

	2025	2024
Share price at grant date	\$25.22	\$22.99
Exercise price	\$24.64	\$22.95
Expected volatility	30.8%	32.1%
Option life (in years) ⁽ⁱⁱ⁾	4.5	4.5
Expected dividend yield	4.5%	4.6%
Risk-free interest rate(iii)	2.5%	3.6%

⁽i) Weighted average based on number of units granted.

There were no stock options granted during the three months ended June 30, 2025 and 2024. Expenses relating to current and prior year options during the three months ended June 30, 2025 were \$1.3 million (2024: \$1.3 million).

The fair value of options granted during the six months ended June 30, 2025 was \$4.1 million (2024: \$7.9 million). Expenses relating to current and prior year options during the six months ended June 30, 2025 were \$2.8 million (2024: \$3.2 million).

⁽ii) Expected weighted average life.

⁽iii) Based on Government of Canada bonds.

Restricted Share Units and Performance Share Units

A summary of the status of the Company's Restricted Share Units ("RSUs") and Performance Share Units ("PSUs") plans as at and for the six months ended June 30 are presented below:

	202	2025			2024			
	Share units outstanding	fa	eighted average air value at grant	Share units outstanding		Veighted average air value at grant		
Outstanding at January 1	3,224,990	\$	21.38	2,018,396	\$	23.87		
Granted	925,790	\$	22.11	1,818,035	\$	20.67		
Forfeited	(29,262)	\$	21.17	(34,260)	\$	23.04		
Outstanding at March 31	4,121,518	\$	21.54	3,802,171	\$	22.35		
Distributed	(533,478)	\$	24.21	(262,532)	\$	24.08		
Forfeited	(377,599)	\$	25.85	(255,553)	\$	24.04		
Outstanding at June 30	3,210,441	\$	20.59	3,284,086	\$	21.36		

There were no RSUs and PSUs granted during the three months ended June 30, 2025 and 2024. Expenses for the three months ended June 30, 2025 relating to current and prior year RSUs and PSUs, were \$5.4 million (2024: \$5.1 million), of which \$0.6 million (2024: \$0.5 million) will be paid in cash and the remainder settled in shares.

The fair value of RSUs and PSUs granted during the six months ended June 30, 2025, was \$17.2 million (2024: \$30.7 million). Expenses for the six months ended June 30, 2025 relating to current and prior year RSUs and PSUs were \$9.9 million (2024: \$8.0 million), of which \$1.2 million (2024: \$0.6 million) will be paid in cash and the remainder settled in shares.

A portion of the outstanding RSUs and PSUs will be settled in cash. The total liability recorded for these units is \$2.1 million (June 30, 2024: \$1.2 million, December 31, 2024: \$1.7 million).

The key assumptions used in the valuation of fair value of RSUs and PSUs granted during the six months ended June 30, 2025 and 2024 are shown in the table below⁽ⁱ⁾:

	2025	2024
Expected RSU life (in years)	3.0	2.6
Forfeiture rate	16.1%	12.6%
Risk-free interest rate ⁽ⁱⁱ⁾	2.5%	4.0%

Weighted average based on number of units granted.

Deferred Share Units

Expenses for the three and six months ended June 30, 2025 relating to deferred share units were \$0.6 million and \$1.0 million (2024: \$0.4 million and \$0.8 million).

⁽ii) Based on Government of Canada bonds.

14. GEOGRAPHIC AND CUSTOMER PROFILE

Information About Geographic Areas

The following summarizes sales by country of origin:

	Three months	Three months ended June 30, Six months ended Jure			
	2025	2024	2025	2024	
Canada ⁽ⁱ⁾	\$ 1,007,679	\$ 943,554	\$ 1,906,459	\$ 1,792,466	
U.S.	131,556	130,501	270,037	253,232	
Japan	113,749	92,732	214,229	186,292	
China	15,644	16,890	30,899	30,418	
Other	93,516	71,496	181,813	140,056	
Sales	\$ 1,362,144	\$ 1,255,173	\$ 2,603,437	\$ 2,402,464	

⁽i) Quarterly amounts for 2024 have been adjusted, see Note 16.

The following summarizes the location of non-current assets by country:

	As at June 30,	As at June 30, As at June 30,	
	2025	2024	2024
Canada	\$ 2,816,922	\$ 2,939,471	\$ 2,862,830
U.S.	278,283	297,020	303,349
Other	945	270	234
Total non-current assets ⁽ⁱ⁾	\$ 3,096,150	\$ 3,236,761	\$ 3,166,413

Excludes financial instruments, investments designated as financial instruments, employee benefits, and deferred tax assets.

Information About Major Customers

For the three months ended June 30, 2025, the Company reported sales to two customers representing 12.8% and 10.8% (2024: 11.9% and 12.0%) of total sales. No other sales were made to any one customer that represented in excess of 10.0% of total sales.

For the six months ended June 30, 2025, the Company reported sales to two customers representing 12.7% and 11.1% (2024: 12.3% and 12.3%) of total sales. No other sales were made to any one customer that represented in excess of 10.0% of total sales.

15. RELATED PARTY TRANSACTIONS

The Company sponsors a number of defined benefit, defined contribution and post-retirement benefit plans. During the three and six months ended June 30, 2025, the Company contributed \$7.7 million and \$15.9 million (2024: \$8.2 million and \$15.6 million) to these plans.

The Company's largest shareholder is McCain Capital Inc. ("MCI"). The Company has been informed that Mr. Michael H. McCain, Executive Chairman of the Board, is the controlling shareholder of MCI. For the three and six months ended June 30, 2025, the Company received services from MCI and companies directly or indirectly owned by MCI in the amount of \$0.2 million and \$0.3 million (2024: \$0.2 million and \$0.3 million), which represented the market value of these transactions. As at June 30, 2025, \$0.3 million (June 30, 2024: \$0.2 million; December 31, 2024: \$0.2 million) was owed to MCI and companies directly or indirectly owned by MCI relating to these transactions.

McCain Financial Advisory Services ("MFAS"), is an entity jointly controlled by individuals including Mr. Michael H. McCain. For the three and six months ended June 30, 2025 and 2024, the Company provided services to and received services from MFAS for a nominal amount which represented the market value of the transactions.

16. ADJUSTMENT OF COMPARATIVE INFORMATION

Prior year sales and cost of goods sold have both been adjusted to reduce each balance for the three and six months ended by \$5.7 million and \$11.6 million, respectively, from the previously published amounts in order to eliminate agreements that contained an expectation of repurchase and had previously been reported as external sales and cost of goods sold.

	Three months ended June 30, 2024				Six months ended June 30, 2024			
	As reported		Change	As adjusted	As reported		Change	As adjusted
Sales	\$ 1,260,878	\$	(5,705)	\$ 1,255,173	\$ 2,414,103	\$	(11,639)	\$ 2,402,464
Cost of goods sold	1,129,723		(5,705)	1,124,018	2,056,608		(11,639)	2,044,969
Gross profit	\$ 131,155		_	\$ 131,155	\$ 357,495		_	\$ 357,495